Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

15
Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
15
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

24
Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
24
Viral Meningitis01:18

Viral Meningitis

199
Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...
199
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Vaccine Production01:23

Vaccine Production

144
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
144
Encephalitis l: Introduction01:19

Encephalitis l: Introduction

15
Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...
15

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health care utilization and cost implications of Chile's 2024 nirsevimab strategy for RSV prevention: a counterfactual analysis.

Lancet regional health. Americas·2026
Same author

Nirsevimab in High-Risk Infants in a Respiratory Syncytial Virus Prevention Strategy.

JAMA network open·2026
Same author

Safety, tolerability, and immunogenicity of a 31-valent pneumococcal conjugate vaccine (VAX-31) in healthy adults aged 50 years and older from the USA: a phase 1/2, double-blinded, active-controlled, parallel-group, dose-finding randomised clinical trial.

The Lancet. Infectious diseases·2026
Same author

Report of a one-day convening on regulatory science, practices, and innovative approaches to facilitate approval of novel combination vaccines.

Vaccine·2026
Same author

The role of HPV single-dose vaccination in expanding access in GAVI-supported countries during a period of supply constraints.

Vaccine·2026
Same author

Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): a retrospective observational study.

The Lancet. Infectious diseases·2025

Related Experiment Video

Updated: May 4, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
10:03

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

7.0K

A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program.

Miguel O'Ryan1, Jeffrey Stoddard, Daniela Toneatto

  • 1Programa de Microbiología y Micología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Avda Independencia 1027, Santiago, Chile, moryan@med.uchile.cl.

Drugs
|December 17, 2013
PubMed
Summary

The four-component meningococcal B vaccine (4CMenB) shows promising efficacy and a favorable safety profile in infants and adolescents. This vaccine offers broad protection against diverse meningococcal B strains globally.

More Related Videos

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

2.9K
Induction of Leptomeningeal Cells Modification Via Intracisternal Injection
05:55

Induction of Leptomeningeal Cells Modification Via Intracisternal Injection

Published on: May 7, 2020

8.0K

Related Experiment Videos

Last Updated: May 4, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
10:03

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

7.0K
Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

2.9K
Induction of Leptomeningeal Cells Modification Via Intracisternal Injection
05:55

Induction of Leptomeningeal Cells Modification Via Intracisternal Injection

Published on: May 7, 2020

8.0K

Area of Science:

  • Immunology
  • Vaccinology
  • Microbiology

Background:

  • Meningococcal B disease remains a significant public health concern.
  • Existing vaccines offer limited protection against serogroup B strains.
  • The development of a broadly protective meningococcal B vaccine is a priority.

Purpose of the Study:

  • To review the clinical development program of the four-component meningococcal B vaccine (4CMenB).
  • To evaluate the safety and immunogenicity of 4CMenB in infants, adolescents, and adults.
  • To assess the potential global coverage of 4CMenB against meningococcal B strains.

Main Methods:

  • Review of pivotal phase I/IIb/III clinical trials involving over 7,000 participants.
  • Assessment of immunological correlates for protection using human complement-mediated serum bactericidal activity.
  • Analysis of safety data, including solicited and unsolicited adverse events.

Main Results:

  • A four-dose schedule for infants and a two-dose schedule for adolescents demonstrated optimal results based on protective antibody titers.
  • Adverse events such as injection site pain, fever, and malaise were mostly mild to moderate.
  • No significant increase in the frequency of rare events like Kawasaki disease or juvenile arthritis was observed compared to unvaccinated individuals.

Conclusions:

  • 4CMenB is a safe and effective vaccine for preventing meningococcal B disease in infants and adolescents.
  • The vaccine is estimated to provide substantial global coverage against circulating meningococcal B strains.
  • 4CMenB represents a significant advancement in the control of meningococcal B infections.